Table 1.

Baseline characteristics of TOURMALINE study patients included in the efficacy population

ParameterValue, N=112
Age
 Years, mean (SD)67 (12)
 ≥65 yr, n (%)73 (65)
Men, n (%)73 (65)
Race, n (%)
 White92 (82)
 Black14 (13)
 Other4 (4)
Ethnicity, n (%)
 Hispanic/Latino63 (56)
 Non-Hispanic/Latino49 (44)
Serum potassium, mEq/L, mean (SD)5.39 (0.40)a
 <5.5, n (%)66 (59)
 ≥5.5, n (%)46 (41)
eGFR, mean (SD), ml/min per 1.73 m241 (26)
CKD, n (%)85 (76)
 eGFR≥45 ml/min per 1.73 m216 (14)
 eGFR<45 ml/min per 1.73 m269 (62)
Diabetes mellitus, n (%)92 (82)
Heart failure, n (%)10 (9)
Hypertension, n (%)105 (94)
RAAS inhibitors, n (%)66 (59)
β-Blocking agents, n (%)58 (52)
Non-RAAS diuretic, n (%)40 (36)b
  • RAAS, renin-angiotensin-aldosterone system.

  • a Baseline serum potassium is defined as the mean of serum potassium from the central laboratory on two consecutive days (day −1 and day 1) immediately before the first dose of patiromer.

  • b All non-RAAS diuretics were potassium wasting.